Regions Financial Corp Vertex Pharmaceuticals Inc Transaction History

Regions Financial Corp

$13.8 Billion
Q3 2024

A detailed history of Regions Financial Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Regions Financial Corp holds 1,008 shares of VRTX stock, worth $412,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,008

Previous 1,024 1.56%

Holding current value

$412,030

Previous $479,000 2.3%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $7,360 - $8,092	-16 Reduced 1.56%	1,008 $468,000
Q2 2024 Jul 31, 2024	BUY	$392.81 - $485.53 $106,058 - $131,093	270 Added 35.81%	1,024 $479,000
Q1 2024 Apr 23, 2024	BUY	$407.69 - $446.08 $22,015 - $24,088	54 Added 7.71%	754 $315,000
Q4 2023 Feb 06, 2024	SELL	$343.0 - $410.68 $193,795 - $232,034	-565 Reduced 44.66%	700 $284,000
Q3 2023 Nov 01, 2023	SELL	$338.18 - $362.46 $3,381 - $3,624	-10 Reduced 0.78%	1,265 $439,000
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $8,803 - $9,853	-28 Reduced 2.15%	1,275 $448,000
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $17,560 - $20,032	-62 Reduced 4.54%	1,303 $411,000
Q4 2022 Feb 03, 2023	SELL	$285.76 - $321.48 $571 - $642	-2 Reduced 0.15%	1,365 $394,000
Q3 2022 Nov 03, 2022	SELL	$273.83 - $305.53 $107,341 - $119,767	-392 Reduced 22.29%	1,367 $396,000
Q2 2022 Jul 25, 2022	SELL	$234.96 - $292.55 $72,132 - $89,812	-307 Reduced 14.86%	1,759 $495,000
Q1 2022 Apr 25, 2022	SELL	$221.42 - $260.97 $210,791 - $248,443	-952 Reduced 31.54%	2,066 $539,000
Q4 2021 Jan 31, 2022	SELL	$177.01 - $223.45 $238,255 - $300,763	-1,346 Reduced 30.84%	3,018 $663,000
Q3 2021 Nov 04, 2021	SELL	$181.39 - $202.99 $1.39 Million - $1.56 Million	-7,668 Reduced 63.73%	4,364 $791,000
Q2 2021 Jul 27, 2021	SELL	$187.49 - $221.1 $10.1 Million - $11.9 Million	-53,803 Reduced 81.72%	12,032 $2.43 Million
Q1 2021 Jun 02, 2021	SELL	$207.02 - $241.31 $1.65 Million - $1.92 Million	-7,951 Reduced 10.78%	65,835 $14.1 Million
Q4 2020 Feb 05, 2021	SELL	$207.01 - $276.09 $55,892 - $74,544	-270 Reduced 0.36%	73,786 $17.4 Million
Q3 2020 Oct 15, 2020	BUY	$255.65 - $303.1 $1.47 Million - $1.74 Million	5,750 Added 8.42%	74,056 $20.2 Million
Q2 2020 Jul 27, 2020	BUY	$225.48 - $295.8 $1.56 Million - $2.04 Million	6,911 Added 11.26%	68,306 $19.8 Million
Q1 2020 Apr 29, 2020	SELL	$199.77 - $247.81 $293,462 - $364,032	-1,469 Reduced 2.34%	61,395 $14.6 Million
Q4 2019 Feb 03, 2020	SELL	$166.71 - $223.91 $30,341 - $40,751	-182 Reduced 0.29%	62,864 $13.8 Million
Q3 2019 Oct 24, 2019	BUY	$166.23 - $187.09 $731,578 - $823,383	4,401 Added 7.5%	63,046 $10.7 Million
Q2 2019 Jul 19, 2019	BUY	$164.61 - $190.37 $2.09 Million - $2.41 Million	12,672 Added 27.56%	58,645 $10.8 Million
Q1 2019 Apr 19, 2019	BUY	$163.73 - $194.7 $7.24 Million - $8.61 Million	44,231 Added 2539.09%	45,973 $8.46 Million
Q4 2018 Jan 28, 2019	SELL	$151.91 - $192.21 $320,074 - $404,986	-2,107 Reduced 54.74%	1,742 $288,000
Q3 2018 Oct 22, 2018	SELL	$167.73 - $192.74 $173,768 - $199,678	-1,036 Reduced 21.21%	3,849 $742,000
Q2 2018 Jul 26, 2018	SELL	$145.72 - $169.96 $314,463 - $366,773	-2,158 Reduced 30.64%	4,885 $831,000
Q1 2018 Apr 18, 2018	SELL	$151.6 - $177.13 $382,941 - $447,430	-2,526 Reduced 26.4%	7,043 $1.15 Million
Q4 2017 Jan 18, 2018	SELL	$137.28 - $155.55 $244,083 - $276,567	-1,778 Reduced 15.67%	9,569 $1.43 Million
Q3 2017 Oct 23, 2017	BUY	$148.13 - $162.24 $1.68 Million - $1.84 Million	11,347	11,347 $1.73 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Regions Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Regions Financial Corp with notifications on news.

Account

Regions Financial Corp Vertex Pharmaceuticals Inc Transaction History